EPSILOGEN
8.7.2024 08:01:30 CEST | Business Wire | Press release
Epsilogen, a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer, today announces that the Clinical Trial Application for the Phase Ib trial of MOv18 IgE has been approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA).
The Phase Ib study is expected to initiate later in 2024 and will evaluate the efficacy of MOv18 IgE in patients with platinum-resistant ovarian cancer (PROC).
Dr Tim Wilson, Chief Executive Officer of Epsilogen, said: “This CTA is another significant milestone for Epsilogen and the clinical development of MOv18 IgE. We look forward to progressing MOv18 IgE into a Phase Ib efficacy study later this year as we continue to demonstrate the potential of IgE antibodies as a new, differentiated class of cancer treatments.”
About MOv18 IgE
MOv18 IgE is an immunoglobulin E (IgE) antibody targeting the folate receptor alpha (FR alpha) antigen. FR alpha is present on a variety of cancers including ovarian, endometrial, lung and triple negative breast cancer. Epsilogen has successfully completed a Phase I safety study of MOv18 IgE in PROC patients. The results of the study, published in Nature Communications, found MOv18 IgE to be safe and well tolerated, with evidence of anti-tumour activity observed. Epsilogen, alongside its partner Lonza, also announced the successful completion of large-scale Good Manufacturing Practice (GMP) manufacturing of MOv18 IgE earlier this year.
About the Phase Ib study
The Phase Ib study is designed to confirm the safety and tolerability of MOv18 IgE and demonstrate efficacy in PROC. Following the dose escalation, an expansion cohort will be recruited to make a preliminary assessment of the anti-tumour activity of MOv18 IgE at a selected dose. In addition, delay to disease progression will be assessed along with a number of translational elements to generate further understanding of MOv18 IgE in the study population.
About Epsilogen Ltd
Epsilogen is a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer. IgE’s natural function is to provide immunological defence against certain parasites. This functionality makes it an ideal treatment of solid tumours due to its strong potency, enhanced tumour access and long tissue half-life.
Epsilogen’s lead product candidate, MOv18 IgE, is the first therapeutic IgE antibody to enter the clinic and encouraging data from a completed Phase I trial demonstrated MOv18 IgE to be safe and well tolerated with early signs of clinical activity. Epsilogen has recently successfully completed large scale GMP manufacture of MOv18 IgE (the first time this has been achieved for an IgE antibody) and will initiate a Phase Ib trial in platinum-resistant ovarian cancer patients later this year. The company is also developing a pipeline of IgE therapies in oncology as well as proprietary platforms including IgE bispecifics and unique IgE/IgG combination antibody molecules (IgEGs) with enhanced functionality.
Epsilogen began operations in 2017 as a spin-out of King’s College London and has attracted venture capital financing from Epidarex Capital, Novartis Venture Fund, 3B Future Health, British Patient Capital, ALSA Ventures and Schroders Capital amongst others. Find out more at epsilogen.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240707808760/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Global Database Launches Regis, an AI Assistant for Live Company Registry Data30.6.2026 11:13:00 CEST | Press release
Regis gives business users a ChatGPT-like experience for company research, compliance checks, ownership discovery, financial analysis, and prospect list building — powered by live data from official government registries Global Database today announced the launch of Regis, a new AI assistant designed to answer business questions using live company data from official government registries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630229011/en/ Unlike general-purpose AI tools that rely on training data or open web sources, Regis is connected to Global Database’s structured company intelligence platform, covering more than 600 million company profiles, sourced from over 400 government registries across more than 200 countries. For more than a decade, Global Database has been collecting, structuring, and maintaining company data directly from government registries around the world. With the launch of Regis, the company
Kraken Goes Live on Trever to Bring Full-Service Prime Brokerage to European Financial Institutions30.6.2026 10:30:00 CEST | Press release
European banks, brokers and other licensed financial institutions using Trever can now access Kraken Prime’s institutional crypto trading and qualified custody Kraken Prime, the full-service prime brokerage offering trading, qualified custody and other financial services through an integrated platform, is now available through Trever, the operating standard in digital asset banking. Trever’s Digital Asset Operating System is used by financial institutions across Europe to manage the full digital asset lifecycle within a single environment – including trading, treasury, settlement and bookkeeping. From today, banks and brokers using Trever can route execution, settle into qualified custody, record all transactions and access other services through Kraken Prime without leaving their existing operational environment. The integration extends Trever’s connectivity, bringing a prime brokerage relationship into the existing workflows institutional teams use across their digital asset operatio
Microsoft Takes Sisvel Wi-Fi Multimode Patent Pool Licence30.6.2026 10:17:00 CEST | Press release
Microsoft has become a licensee of the Sisvel Wi-Fi Multimode pool. The US computer and software giant is the latest in a string of major companies to take a licence to the standard essential patents offered through the programme. In doing so, it joins ASUS, Hewlett Packard Enterprise and Sony Group Corporation, as well as Huawei, Panasonic, Philips and ZTE which are also pool licensors alongside KPN, Mitsubishi Electric, Orange, Aegis 11 (a Sisvel affiliate), SK Telecom and Wilus. The Sisvel Wi-Fi Multimode pool covers both Wi-Fi 6 and Wi-Fi 7 and offers an efficient way to access essential Wi-Fi rights for years to come. It was publicly launched in January 2026 as the successor to the Sisvel Wi-Fi 6 patent pool. Over a three-year period under that programme, agreements were closed with 40 companies, including Acer, Netgear, Cisco and HP. “It is a pleasure to welcome Microsoft as a licensee of the Sisvel Wi-Fi Multimode pool,” says Alex Debski, Director of Licensing and Counsel Legal
STOKR Secures CASP and PI Licences in Luxembourg Ahead of MiCAR Deadline30.6.2026 10:00:00 CEST | Press release
Authorised by the CSSF just before the 1 July 2026 enforcement deadline, STOKR joins a small group of crypto-asset firms cleared to operate across the EU under a single, harmonised regime. STOKR, the Luxembourg-based digital securities platform, has received authorisation from the Commission de Surveillance du Secteur Financier (CSSF) under the EU's Markets in Crypto-Assets Regulation (MiCAR) and the Law of 10 November 2009 on payment services, securing its Crypto-Asset Service Provider (CASP) and Payment Institution (PI) licences just over a week before MiCAR's 1 July 2026 enforcement deadline. Digital securities fall outside MiCAR's scope but the payment leg does not. To receive, hold, and transfer crypto assets and stablecoins on behalf of clients during subscription and redemption, a platform requires a CASP licence under MiCAR and a PI. Without both, a platform can issue digital securities but cannot move the capital. With MiCAR's transitional period ending on 30 June 2026, a sign
NHOA Energy Awarded Culcairn Battery Contract by Neoen in Australia30.6.2026 09:06:00 CEST | Press release
The landmark Culcairn Battery contract builds on the successful delivery of Neoen’s Blyth Battery by NHOA Energy in Australia, strengthening the long-standing relationship between both companies NHOA Energy, global provider of utility-scale energy storage systems, has been awarded notice-to-proceed by Neoen, one of the world’s leading renewable energy companies, on the latter’s Culcairn Battery, a 215 MW / 963 MWh project to be installed in New South Wales (NSW), Australia. The project will be delivered under an EPC contract in partnership with a joint venture between Equans Solar & Storage and Bouygues Construction Australia and marks a significant new milestone in the long-standing partnership between Neoen and NHOA Energy in Australia. The announcement follows the successful delivery of work by NHOA Energy on Neoen’s 238.5 MW / 477 MWh Blyth Battery in South Australia, in operation since early 2025, and reaffirms NHOA Energy’s leading role in the growth of large-scale energy storage
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom